Public Sector Pension Investment Board Raises Stake in Collegium Pharmaceutical, Inc. $COLL

Public Sector Pension Investment Board increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 11.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 122,899 shares of the specialty pharmaceutical company’s stock after buying an additional 13,104 shares during the period. Public Sector Pension Investment Board’s holdings in Collegium Pharmaceutical were worth $4,300,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Millennium Management LLC lifted its stake in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after acquiring an additional 461,914 shares during the period. Rubric Capital Management LP lifted its position in Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after purchasing an additional 157,743 shares during the period. Loomis Sayles & Co. L P boosted its holdings in Collegium Pharmaceutical by 79.9% in the second quarter. Loomis Sayles & Co. L P now owns 337,137 shares of the specialty pharmaceutical company’s stock valued at $9,969,000 after purchasing an additional 149,766 shares during the last quarter. Marshall Wace LLP purchased a new stake in Collegium Pharmaceutical in the second quarter valued at $4,043,000. Finally, Assenagon Asset Management S.A. grew its position in Collegium Pharmaceutical by 90.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock worth $6,844,000 after purchasing an additional 92,898 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on COLL shares. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a report on Tuesday, February 10th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Needham & Company LLC boosted their target price on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. The trade was a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $45.18 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $50.79. The business’s 50 day moving average is $47.04 and its two-hundred day moving average is $41.54. The company has a market capitalization of $1.43 billion, a P/E ratio of 28.06 and a beta of 0.64.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.